Our Offering

Genetic Testing Services for stratifying participants and assessing Alzheimer’s disease risk

Precision medicine research assay available globally as early access service

Cytox now offers Genetic Testing Services to help clinical researchers and BioPharma stratify samples obtained from clinical trial subjects who are pre-symptomatic or showing mild cognitive impairment (MCI) and are at risk of developing Alzheimer’s disease (AD), including those with negative ApoE4 genotypes. The services provide new tools to progress academic research, and will be ideal in novel drug discovery, clinical research or to assist Biopharma companies in stratifying subjects for early stage clinical trials or companion diagnostic development for transformation in Alzheimer’s disease care.

Cytox has launched this breakthrough following multiple clinical research validation studies on over 1000 samples jointly run by the company and our global academic research collaborators. The research use single nucleotide polymorphism (SNP) profiling array, variaTECT™, used in combination with analysis by our proprietary SNPfitR™ interpretive software is currently the most comprehensive research panel available for the detection of AD informative SNPs, providing an accuracy of greater than 80%, with high positive and negative predictive values for the amyloid status of test subjects. This high degree of accuracy dramatically reduces the screening failure rate and current associated costs of testing for amyloid positivity using PET amyloid or CSF examinations, which are not well-suited for high volume screening. Simply requiring gDNA, e.g. from a blood sample or clinical sample archive, the service is high throughput and runs on the commercially proven Affymetrix Axiom®/ GeneTitan® platform.

If you are interested in running a study and require further information, please contact enquiries@cytoxgroup.com

Cytox variaTECT™ SNP Research Array

Genetic biomarker research assay to help reduce screening failure in clinical trials and assist novel drug discovery

Cytox, in partnership with Thermo Fisher Scientific, has now developed a research array for assessing Alzheimer’s disease (AD) risk. The Cytox variaTECT™ SNP (single nucleotide polymorphism) array is currently the most comprehensive panel available for the detection of AD informative SNPs, comprising approximately 130,000 novel and known SNP variants in genes pertaining to pathways implicated in AD aetiology.

The variaTECT panel is designed to run on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform. The array is easy to administer and simply requires gDNA, e.g. from a blood sample or clinical sample archive.

A combination of whole exome association analysis (testing protein-encoding genetic variants across the genome in highly selected and characterised clinical samples), variations identified through Genome Wide Association studies and variants considered to be of importance in AD-associated biological pathways, are included on the variaTECT array. Disease risk prediction modelling has been further applied to quantify the utility of the associated variants. The variaTECT SNP array comprises: Cytox panel approx. 17,000, Research panel approx. 8,750, mTOR panel approx. 39,500, UK Biobank panel approx. 23,750, IGAP panel approx. 37,000, Meta-analysis panel approx. 3,000 SNPs.

The variaTECT SNP array can be used together with Cytox’s new SNPfitR™ interpretive software to enrich amyloid-positive cohorts and so reduce screening failure rates in early symptomatic (Mild Cognitive Impairment – MCI) and pre-symptomatic subject groups. The assay has an accuracy of greater than 80%, with high positive and negative predictive values for the amyloid status of test subjects [1, 2].

The variaTECT SNP array is ideal to support users in the pharmaceutical industry in reducing the screening failure rate in finding amyloid positive subjects for recruitment into clinical trials, with potential for huge savings in cost and time, and to assist both academic and commercial researchers in the pharma/biotech fields involved in the development of potential new Alzheimer’s disease treatments and for related biobank and longitudinal study cohorts.

For further information please contact enquiries@cytoxgroup.com

References

1. Shoai, M. et al. Evaluation of a Novel Array of SNP Markers in Amyloid-PET Stratified Samples from MCI and Cognitively Normal Individuals. P4-126, AAIC 2016.

2. Hampel, H. et al. Alzheimer’s Disease Detection at the Preclinical Stage Using a Novel SNP Genotyping Array. P4-111, AAIC 2016.

Cytox SNPfitR™ interpretive software

Array analysis will identify amyloid-positive subjects more efficiently and reduce screening failure rates in clinical trials

Cytox SNPfitR™ is the software and polygenic risk score algorithm for the analysis of the variaTECT genotyping microarray plates.

variaTECT microarray plates are configured particularly to include SNPs (single nucleotide polymorphisms) of relevance to the determination of the risk of Alzheimer’s disease.

SNPfitR software is dedicated primarily for the analysis of variaTECT plate genotyping results and will provide support to both academic and commercial researchers in the pharma/biotech fields involved in the development of potential new Alzheimer’s disease treatments and for related biobank and longitudinal study cohorts.

The variaTECT plates are processed on an Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument. SNPfitR is designed to run on Windows based workstations.

For further information please contact enquiries@cytoxgroup.com

 

For Research Use Only. Not for use in diagnostic procedures.

 

Socials

Connect with Cytox!

Back to Top